ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NERV
08 janv. 2021 17h08 HE
|
The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN
18 nov. 2020 13h08 HE
|
The Rosen Law Firm PA
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13,...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
24 sept. 2020 07h00 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
23 sept. 2020 19h30 HE
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has submitted a New Drug Application...
FDA Approves SCENESSE® For Genetic Disorder
08 oct. 2019 19h11 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- The US Food and Drug Administration (FDA) has approved a new drug as the first ever treatment for a rare genetic metabolic disorder which...
Melinta Therapeutics Announces U.S. FDA Acceptance of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia
19 juin 2019 07h30 HE
|
Melinta Therapeutics
~ Application Seeks to Expand Label to Include an Indication and Phase III Data for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia (CABP) ~ ~ PDUFA Date Set for October...
FDA to Review Australian Drug for Genetic Disorder of Absolute Light Intolerance
25 juin 2018 06h00 HE
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- In a landmark case, the US Food and Drug Administration (FDA) has begun a review of an innovative drug developed for patients who carry a rare...
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Antares Pharma, Inc.
25 oct. 2017 15h46 HE
|
Federman & Sherwood
OKLAHOMA CITY, Oct. 25, 2017 (GLOBE NEWSWIRE) -- Federman & Sherwood announces that on October 23, 2017, a class action lawsuit was filed in the United States District Court for the District of...
Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old
19 juin 2017 21h46 HE
|
Neos Therapeutics, Inc
DALLAS and FORT WORTH, Texas, June 19, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
Melinta Therapeutics Provides Baxdela NDA Update
27 févr. 2017 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 27, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company focused on developing novel antibiotics to treat serious bacterial infections, today announced that...